Research Project

Project Title:	A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (lgAN)
Project Type:	Clinical Trial, Enrolment ongoing
Disease group(s):	Immune glomerulopathies
Project Summary:	A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (lgAN)
Lead principal investigator(s):	Loreto Gesualdo, Bari
Co-investigator(s):	Vincenzo Di Leo, Bari
Project Period:	01/2022 - 06/2026
EudraCT Nr.:	2021-001426-22